dihydrostreptomycin

Dihydrostreptomycin is a semisynthetic aminoglycoside antibiotic and a derivative of streptomycin. It exhibits bactericidal activity by irreversibly binding to the S12 protein in the bacterial 30S ribosomal subunit after active transport into the cell. This disrupts initiation complex formation between mRNA and the ribosome and leads to synthesis of defective proteins that result in bacterial cell death. Dihydrostreptomycin has been used primarily for tuberculosis treatment but is no longer approved for human use due to its ototoxicity (hearing loss risk). Its primary mechanism involves inhibition of bacterial protein synthesis[3][6][8].

Other names

N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-(hydroxymethyl)-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine1,1'-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-(hydroxymethyl)-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine2,4-Diguanidino-3,5,6-trihydroxycyclohexyl-5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-hydroxymethyl-beta-L-lyxo-pentanofuranoside